LivaNova (NASDAQ:LIVN) Price Target Raised to $70.00

LivaNova (NASDAQ:LIVN) had its price objective upped by Stifel Nicolaus from $65.00 to $70.00 in a research report released on Wednesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other research analysts have also recently weighed in on LIVN. Weiss Ratings restated a “sell (d+)” rating on shares of LivaNova in a research note on Monday, December 29th. The Goldman Sachs Group set a $55.00 target price on LivaNova and gave the stock a “neutral” rating in a research report on Wednesday, October 1st. Mizuho raised their price target on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. KeyCorp initiated coverage on shares of LivaNova in a report on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective for the company. Finally, Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $69.38.

LivaNova Trading Down 0.8%

Shares of NASDAQ LIVN opened at $64.41 on Wednesday. The firm’s 50 day moving average price is $60.10 and its 200-day moving average price is $54.02. LivaNova has a 52-week low of $32.48 and a 52-week high of $65.57. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.12 and a current ratio of 1.33. The company has a market cap of $3.52 billion, a PE ratio of -16.10 and a beta of 0.97.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Amundi lifted its position in LivaNova by 7.2% in the first quarter. Amundi now owns 196,435 shares of the company’s stock worth $7,362,000 after buying an additional 13,142 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in shares of LivaNova by 79.6% in the 2nd quarter. New York State Common Retirement Fund now owns 86,741 shares of the company’s stock worth $3,905,000 after acquiring an additional 38,451 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of LivaNova by 20.3% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 102,165 shares of the company’s stock worth $4,599,000 after purchasing an additional 17,252 shares during the period. Aberdeen Group plc grew its holdings in LivaNova by 18.1% during the 2nd quarter. Aberdeen Group plc now owns 326,786 shares of the company’s stock valued at $14,712,000 after purchasing an additional 50,076 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in LivaNova during the 2nd quarter valued at about $1,713,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.